Compare PXED & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | MRVI |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.1M | 1.0B |
| IPO Year | 2025 | 2020 |
| Metric | PXED | MRVI |
|---|---|---|
| Price | $25.83 | $7.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $44.29 | $4.13 |
| AVG Volume (30 Days) | 56.2K | ★ 2.6M |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ 1.69 | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $3.85 | $12.54 |
| Revenue Next Year | $4.49 | $7.87 |
| P/E Ratio | $15.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.52 | $2.55 |
| 52 Week High | $38.19 | $9.42 |
| Indicator | PXED | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 30.31 | 55.31 |
| Support Level | $24.92 | $5.54 |
| Resistance Level | $30.79 | $9.42 |
| Average True Range (ATR) | 0.86 | 0.36 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 12.24 | 79.22 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.